Longeveron Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Longeveron Inc 's ROA in the second quarter of 2026?
Longeveron Inc recorded a cumulative net loss of $-23 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -122.9%.

However, within the Healthcare sector 808 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4381, from total ROA ranking in the first quarter of 2026 at 5076.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	75.38 %	1.74 %	-59.85 %	-47.99 %	-13.63 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-23	-22	-23	-21	-19
Return On Assets (TTM)	-122.9 %	-140.67 %	-143.21 %	-108.46 %	-80.33 %
LGVN's Total Ranking	# 4381	# 5076	# 4412	# 4349	# 4547
Total Assets (TTM) in million	29	21	10	16	17
Seq. Total Assets Change	38.49 %	106.7 %	-34.04 %	-7.12 %	-19.66 %
Seq. Net Income Change	-	-	-	-	-

LGVN's 5 Years Annual ROA >> Back to LGVN Management Effectiveness >> Compare LGVN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 381
Sector	# 809
Overall	# 4358

Return On Assets Statistics
High	Average	Low
-49.93 %	-107.23 %	-211.42 %
(Sep 30 2022)		(Jun 30 2024)

News about Longeveron Inc Return on Assets ROA

Longeveron Appoints Devin Blass as CTO, Prepares for BLA Filing Amid Financial Challenges and Focus on Alzheimer’s Therapy,

In a significant move aimed at bolstering its strategic framework and advancing its scientific endeavors, Longeveron Inc. a pioneering entity in cellular therapies, has announced the appointment of Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing and Controls (CMC), effective December 2, 2024. This transition comes at a pivotal moment for the company as it prepares for a potential Biologics License Application (BLA) filing, which could pave the way for the commercialization of its innovative therapies designed to combat debilitating diseases such as Alzheimer’s.The appointment of Blass, a seasoned expert in the field, underscores Longeveron’s commitment to enhancing its operational capabilities as it navigates the complex regulatory landscape of biotechnology. His vast experience in CMC processes is anticipated to be instrumental in streamlining product development and ensuring compliance with stringent industry standards. This strategic hire is expected to not only solidify Longeveron s position within the regenerative medicine sector but also enhance its efforts to scale the manufacturing processes required for its transformative therapies.

Financial Statements
Longeveron Inc 's Assets	$ 29 million	LGVN's Balance sheet
Longeveron Inc 's Income	$ -6 million	Quarterly LGVN's Income Statement
LGVN's Income by Division		See LGVN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-59.85 %	30.67 %	-28.65 %	-34.38 %	-
Total Assets in million	10	26	20	27	42
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-23	-25	-22	-19	-17
Annual Return On Assets	-221.26 %	-96.34 %	-113.56 %	-68.71 %	-40.8 %

LGVN's 5 Years Annual ROA >> Back to LGVN Management Effectiveness >> Compare LGVN ROA to its Competitors

More Return On Assets Ratios
LGVN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LGVN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LGVN's Competitors
Subscribers only: Roa for Longeveron Inc 's Suppliers
Subscribers only: Return On Assets for LGVN's Customers

You may also want to know
LGVN's Roi	LGVN's Inventory Turnover Ratio	LGVN's Growth Rates	LGVN's Dividend Comparisons
	LGVN's Profitability Ratios	LGVN's Asset Turnover Ratio	LGVN's Dividend Growth
LGVN's Roe	LGVN's Valuation Ratios	LGVN's Financial Strength Ratios	LGVN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T23:54:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.